Sperling Prostate Center

Prostate Cancer and Immunotherapy

Prostate Cancer and Immunotherapy - Sperling Prostate Center
When we posted our first blog on immunotherapy at the start of the 2015 New Year, hopes were rosy that immunotherapies were bringing treatment for metastatic prostate cancer to the brink of a new treatment threshold. Since then, it was found that immunotherapy drugs that worked quite well for other metastatic cancers such as melanoma and certain lung cancers... keep reading

When Will We Have a Liquid Biopsy for Prostate Cancer?

Liquid biopsy - Sperling Prostate Center
The term “liquid biopsy” is appearing with increasing frequency in published literature. The fact that it’s more common than ever does not mean we’ve finally replaced a needle extraction of tissue. However, a blood or urine sample is a far less invasive way to gather a large quantity of information to profile a patient’s prostate cancer (PCa), thanks to numerous biological clues that tumor cells release into the bloodstream. keep reading

“New” Focal Prostate Cancer Treatment? More Questions Than Answers

Radiofrequency ablation for prostate cancer
“Introducing the ultimate technology in Precision Medicine for Prostate Focal Therapy.” “TSPA is the only technology designed for Prostate Focal Therapy” These bold claims announce the availability of Tissue Sparing Prostate Ablation (TSPA), known by its brand name as Encage. Encage uses a specific type of radiofrequency ablation (RFA), which basically cooks a tumor by keep reading

Artificial Intelligence in Medicine: Predicting Prostate Cancer Progression During Active Surveillance

“Despite increasing adoption of active surveillance (AS) for low-risk prostate cancer, AS discontinuation rates are high, investigators report.” This quote, from a September 2021 Renal & Urology News report, referred to a study of over 16,000 Canadian prostate cancer (PCa) patients who had been diagnosed with low risk disease from 2008-2014. 51% of these patients keep reading
WordPress Image Lightbox